Please login to the form below

Not currently logged in
Email:
Password:

Kybella

This page shows the latest Kybella news and features for those working in and with pharma, biotech and healthcare.

Allergan adds Zeltiq to M&A roster in $2.48n deal

Allergan adds Zeltiq to M&A roster in $2.48n deal

Other deals in the aesthetics sector include Allergan's $2.1bn purchase of Kythera in 2015, bringing in double chin-reducing therapy Kybella (deoxycholic acid), and the takeover of regenerative medicine

Latest news

  • Allergan buys regenerative medicine firm LifeCell for $2.9bn Allergan buys regenerative medicine firm LifeCell for $2.9bn

    Those are headed by blockbuster wrinkle treatment Botox but also include Kybella - bought along with Kythera last year for $2.1bn - for reducing double chins and dermal filler Juvederm.

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    Kythera Biopharma created a new therapeutic category in the pharma/cosmetic area with Kybella (deoxycholic acid), the first drug for reducing double chin, while Sprout Pharma chalked up the first approval ... Kybella. submental contouring (double chin).

  • Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera

    Kybella (deoxycholic acid) was approved by the FDA in April and is administered by injection into the chin in order to break down "submental" fat. ... The company's chief executive Brent Saunders also suggested Allergan would be able to speed up the

  • Kythera bags FDA approval for double chin therapy Kythera bags FDA approval for double chin therapy

    Perhaps mindful that Kybella could also be a target, Kythera is launching the product with a holographic label that will make it easier for healthcare practitioners to identify genuine product. ... Kythera has also filed for approval of Kybella in Canada,

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals in June 2015 Pharma deals in June 2015

    When Kybella  is injected into subcutaneous fat, it causes the destruction of fat cells and, once destroyed, these cells cannot store or accumulate fat. ... Kythera Biopharmaceuticals/ Allergan. Rx aesthetic medicine products - incl Kybella  for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics